UPDATE 5-GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover

6

* Deal values cancer drug developer Nuvalent at $124 per share * That is a 40% premium to the US-listed firm's close on Monday * GSK CEO Miels says deals expands lung cancer treatments * Deal size a

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)